Positioning no disclosures inside 60 days, left as found
Options put/call open interest 19.27, read 2026-11-02
Ethical does not pass the values gate
Price37.18 USD
Fair value35.61
Ethical score70.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-11-01Read Markup36.39+2.2% to today ✓Distribution gives way to Markup while volume is distributing
2026-10-28Read Distribution36.62+1.5% to today Markdown gives way to Distribution after a 6% slide in 9 weeks
2026-08-26Read Markdown38.83-4.2% to today ✓Distribution gives way to Markdown after a 5% rise in 8 weeks
2026-07-02Read Distribution36.85+0.9% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
CareTrust REIT Inc holds its Markup at $37.18. Consolidating, no directional conviction, held for 1 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 1 days
Price at the screen
$37.18
Valuation
22.89 trailing · 20.76 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.77
The Workings
Five Screens, Shown in Full
Does not pass. Revenue purity
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
17.37%
Below 33%
Interest-bearing debt is just 17.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
4.05%
Below 49%
Money owed to the company is 4.0% of assets, under the 49% limit.
Pass
Revenue purity
28.96%
Below 5%
29.0% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
CareTrust REIT clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 29% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CTRE's ethical verdict changes
Today CTRE does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades above our $35.61 fair value estimate, weak competitive moat, 43.50% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 4.4% above the base estimate.
Third-party analyst targets: 14 covering, consensus Strong Buy. The average target sits +16% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $35.61, with a range of $35.61 to $40.95, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Healthcare REITs Trading Well Above Fair Value
Nursing homes and senior housing sound like the sort of steady assets that should hold up in any cycle. CareTrust trades well above our fair value with a weak moat and minimal growth, so we pass.
Forward earnings sit at 24.6 times while revenue rises just 3 percent a year. Profit margins look healthy at 64 percent yet a 9 percent return on equity gives little cushion at the current price.
Tenant concentration and rising funding costs can still bite hard in healthcare real estate. The market price already assumes smooth sailing ahead. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CTRE trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup$37.95+3.4%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it strong buy, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markup$36.71+0.9%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it strong buy, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$36.39+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it strong buy, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$36.39+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it strong buy, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup · changed$36.39+0.4%Entry 13
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it strong buy, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Distribution$36.26+0.0%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it strong buy, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Distribution$36.26-1.0%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it strong buy, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Distribution$36.62+0.0%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it strong buy, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it strong buy, with a mean price target of $45.
2026-10-21Markdown$36.59+1.6%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 35%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it strong buy, with a mean price target of $45.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
